share_log

华福证券4月21日发布研报称，给予祥生医疗（688358.SH）买入评级，目标价格为43.01元。评级理由主要包括：1）公司发布2023年年报及2024年一季报；2）2023年业绩符合预期，分红比例亮眼；3）海外增速优异，产品结构持续优化，看好境外持续放量延续高增速；4）在研项目持续中，产品推陈出新将赋能不同临床应用场景。（每日经济新闻）

Huafu Securities released a research report on April 21 stating that it gave Xiangsheng Medical (688358.SH) a purchase rating, with a target price of 43.01 yuan. The main reasons for the rating include: 1) the company released the 2023 annual report and t

Zhitong Finance ·  Apr 21 09:49
Huafu Securities released a research report on April 21 stating that it gave Xiangsheng Medical (688358.SH) a purchase rating, with a target price of 43.01 yuan. The main reasons for the rating include: 1) the company released the 2023 annual report and the 2024 quarterly report; 2) the 2023 performance is in line with expectations, and the dividend ratio is impressive; 3) the overseas growth rate is excellent, the product structure continues to be optimized, and the continued high growth rate is expected; 4) As the research project continues, the introduction of new products will enable different clinical application scenarios. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment